

Variant: *NM_000152.5(GAA):c.2105G>A (p.Arg702His)*

Version: 1.0

[CA8815610](#)

[426278 \(ClinVar\)](#)

Gene: GAA ([HGNC:2548](#))

Condition: glycogen storage disease II ([MONDO:0009290](#))

Inheritance Mode: Autosomal recessive inheritance

UID: 15c8deda-d3b2-4e03-a4c6-3c97f3b96012

Approved on: 2024-03-05

Published on: 2024-03-26

HGVS expressions

NM_000152.5:c.2105G>A

NM_000152.5(GAA):c.2105G>A (p.Arg702His)

NC_000017.11:g.80113282G>A

CM000679.2:g.80113282G>A

NC_000017.10:g.78087081G>A

CM000679.1:g.78087081G>A

NC_000017.9:g.75701676G>A

NG_009822.1:g.16727G>A

ENST00000570803.6:c.2105G>A

ENST00000572080.2:c.*243G>A

ENST00000577106.6:c.2105G>A

ENST00000302262.8:c.2105G>A

ENST00000302262.7:c.2105G>A

ENST00000390015.7:c.2105G>A

ENST00000572080.1:c.524G>A

NM_000152.3:c.2105G>A

NM_001079803.1:c.2105G>A

NM_001079804.1:c.2105G>A

NM_000152.4:c.2105G>A

NM_001079803.2:c.2105G>A

NM_001079804.2:c.2105G>A

NM_001079803.3:c.2105G>A

NM_001079804.3:c.2105G>A

Pathogenic

Met criteria codes **6**

PP4_Moderate **PS3_Supporting**

PM3_Strong **PP3** **PM5**

PM2_Supporting

Evidence Links **0**

Expert Panel

[Lysosomal Diseases VCEP](#)

Criteria Specification Information

Criteria Specification: *ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2*

PDF









Criteria Specification Approval History

Criteria Specifications for this VCEP

Lysosomal Diseases VCEP

The NM_000152.5:c.2105G>A variant in GAA is a missense variant predicted to cause substitution of arginine by histidine at amino acid 702 (p.Arg702His). At least 3 unrelated patients were noted to have deficient GAA activity but results were not provided (PMID: 26310554, 30897595, 28394184). Two patients are described as having IOPD with clinical symptoms consistent with IOPD reported in one (PMID: 26310554). One patient is described as having juvenile-onset Pompe disease with deficient GAA (value not provided) (PMID: 18211760). Another patient is reported to have deficient GAA and late-onset Pompe disease (PMID: 30897595) (PP4_Moderate). At least one patient is described as having this variant in trans with a variant classified as likely pathogenic by the ClinGen Lysosomal Diseases (LD) VCEP (c.796C>T, p.Pro266Ser; ClinVar Variation ID: 556117; SCV002540664.1) (PMID: 18211760). At least two patients have been reported with this variant in compound heterozygosity with another variant that has been classified as pathogenic by the ClinGen LD VCEP (c.2297A>C, p.Tyr766Ser, ClinVar Variation ID: 420102, SCV002540647.1, and c.2238G>C, p.Trp746Cys, ClinVar Variation ID: 265160, SCV002032122.1), phase unconfirmed for both (PMID: 28394184 and 30897595) (PM3_Strong). This variant is absent in gnomAD v2.1.1. (PM2_Supporting). The computational predictor REVEL gives a score of 0.985, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Expression of the variant in COS-7 cells resulted in 5% wild type GAA activity in medium and 13% residual activity in cells with evidence of abnormal synthesizing and processing (PMID: 18425781) leading the variant to be described as Class D “potentially mild” indicating that this variant may impact protein function (PS3_supporting). Another missense variant (c.2105G>T, p.Arg702Leu) in the same codon has been classified as pathogenic for Pompe disease by the ClinGen LD VCEP (ClinVar Variation ID: 92472)(PM5). There is a ClinVar entry for this variant (Variation ID: 426278). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PM3_strong, PM5, PP4_moderate, PM2_supporting, PP3, PS3_supporting.

Met criteria codes

PP4_Moderate	 	At least 3 unrelated patients were noted to have deficient GAA activity but results were not provided (PMID: 26310554, 30897595, 28394184). Two patients are described as having IOPD with clinical symptoms consistent with IOPD reported in one (PMID: 26310554) (PP4). One patient is described as having juvenile-onset Pompe disease with deficient GAA (value not provided) (PMID: 18211760). Another patient is reported to have deficient GAA and late-onset Pompe disease (PMID: 30897595) (PP4_Moderate).
PS3_Supporting	 	Expression of the variant in COS-7 cells resulted in 5% wild type GAA activity in medium and 13% residual activity in cells with evidence of abnormal synthesizing and processing (Kroos et al, 2008 PMID: 18425781) – leading the variant to be described as Class D “potentially mild” indicating that this variant may impact protein function (PS3_supporting).
PM3_Strong	 	At least one patient is described as having this variant in trans with a variant classified as likely pathogenic by the ClinGen LD VCEP (c.796C>T, p.Pro266Ser; ClinVar Variation ID: 556117; SCV002540664.1) (PMID: 18211760) (1 point). At least two patients have been reported with this variant in compound heterozygosity with another variant that has been classified as pathogenic by the ClinGen LD VCEP (c.2297A>C, p.Tyr766Ser, ClinVar Variation ID: 420102, SCV002540647.1, and c.2238G>C, p.Trp746Cys, ClinVar Variation ID: 265160, SCV002032122.1, phase unconfirmed (PMID: 28394184 and 30897595) (2 x 0.5 points). Total 2 points (PM3_Strong).
PP3	 	The computational predictor REVEL gives a score of 0.985, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3).

PM5



Another missense variant [c.2105G>T, p.Arg702Leu] in the same codon has been classified as pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (ClinVar Variation ID: Variation ID: 92472) (PM5).

PM2_Supporting



This variant is absent in gnomAD v2.1.1. (PM2_Supporting). // The highest population minor allele frequency in gnomAD v4.0. is 0.0003 (2/6058 alleles) in the Middle Eastern population, which is lower than the ClinGen Lysosomal Diseases VCEP's threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).

Curation History

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.